REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 21st, 2022 • Precision Biosciences Inc • Biological products, (no disgnostic substances) • Delaware
This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 15, 2022, between Precision BioSciences, Inc., a Delaware corporation (the “Company”), and Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland, with its principal business office located at Lichtstrasse 35, CH-4056 Basel, Switzerland (the “Purchaser”). Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Purchase Agreement (as defined below).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • June 21st, 2022 • Precision Biosciences Inc • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (“Agreement”) is entered into as of June 14, 2022 (the “Execution Date”), by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, having an address at 302 East Pettigrew St. – Dibrell Whse, Suite A-100, Durham, North Carolina 27701-3712, U.S.A. (“Precision”), and Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland, with its principal business office located at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Novartis and Precision are each hereafter referred to individually as a “Party” and together as the “Parties.”
STOCK PURCHASE AGREEMENTRegistration Rights Agreement • June 21st, 2022 • Precision Biosciences Inc • Biological products, (no disgnostic substances) • Delaware
This Stock Purchase Agreement (this “Agreement”) is entered into as of June 14, 2022 (the “Execution Date”), by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, with its principal business office located at 302 E Pettigrew St - Dibrell Whse Suite A-100, Durham, North Carolina 27701-3712 (“Precision”), and Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland, with its principal business office located at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Precision and Novartis are each hereafter referred to individually as a “Party” and together as the “Parties.” The capitalized terms used herein and not otherwise defined have the meanings given to them in Appendix 1 or the Collaboration and License Agreement (as defined below).
